07:00 , Aug 28, 2006 |  BC Week In Review  |  Company News

Athelas, Combinature, MerLion deal

MerLion merged with infectious disease companies Athelas and Combinature in two stock deals. The European companies will become subsidiaries of MerLion, and Combinature CEO Harald Labischinski will become CSO and a director of MerLion. The...
07:00 , Aug 28, 2006 |  BioCentury  |  Strategy

The sun rises in the East

MerLion Pharmaceuticals Pte. Ltd. has decided that it wants to be a public company within two years and has identified Japan as the market in which it wants to debut. With the profile of a...
00:27 , Aug 22, 2006 |  BC Extra  |  Company News

MerLion merges with two companies, raises $25M

In a pair of stock deals, MerLion (Singapore) merged with infectious disease companies Athelas (Geneva, Switzerland) and Combinature (Berlin, Germany). The European companies will become subsidiaries of MerLion , and Combinature CEO Harald Labischinski will...
08:00 , Jan 24, 2005 |  BioCentury  |  Emerging Company Profile

Athelas: Stress trumps atomic bombs

Anyone developing antibiotics is concerned about bacterial resistance. Thus it is no surprise that Athelas Ltd. is using its high throughput screening platform to identify new antibacterial targets that may be less susceptible to resistance....
08:00 , Jan 24, 2005 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Athelas Ltd. Geneva, Switzerland Technology: High throughput in vivo anti-bacterial screening platform Disease focus: Infectious Clinical status: N/A Founded: 2002 by Jean-Pierre Paccaud, Pierre Cosson, Didier Fischer and Leo Cavigelli Corporate partners: MerLion, GeneData University...
07:00 , Apr 14, 2003 |  BC Week In Review  |  Company News

Athelas SA, MerLion deal

Under a two-year deal, MerLion will use assays from Athelas to identify and characterize anti-infective compounds from its sample library. Athelas will be responsible for taking lead compounds into preclinical development, and the companies will...
07:00 , Apr 9, 2003 |  BC Extra  |  Company News

MerLion, Athelas anti-infectives deal

Under a two-year deal, MerLion Pharmaceuticals (Singapore) will use assays from Athelas (Geneva, Switzerland) to identify and characterize anti-infective compounds from its sample library. Athelas will be responsible for taking lead compounds into preclinical development,...